Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah Lewis

Showing results (341-350 of 378) with videos related to

Pageof 38
Sort By:
Muscle & Nerve|August 14, 2023
Long-term safety and functional outcomes of delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy: A phase 1/2a nonrandomized trialJerry R Mendell, Zarife Sahenk, Kelly J Lehman, et al.
The New England Journal of Medicine|October 8, 2010
Dystrophin immunity in Duchenne's muscular dystrophyJerry R Mendell, Katherine Campbell, Louise Rodino-Klapac, et al.
Human Gene Therapy|March 7, 2019
Gene Delivery for Limb-Girdle Muscular Dystrophy Type 2D by Isolated Limb InfusionJerry R Mendell, Louis G Chicoine, Samiah A Al-Zaidy, et al.
Medical Physics|July 15, 2025
Comparison of three reconstruction algorithms for low-dose phase-contrast computed tomography of the breast with synchrotron radiationSandro Donato, Simone Caputo, Luca Brombal, et al.
Annals of Neurology|August 4, 2023
Delandistrogene Moxeparvovec Gene Therapy in Ambulatory Patients (Aged ≥4 to <8 Years) with Duchenne Muscular Dystrophy: 1-Year Interim Results from Study SRP-9001-103 (ENDEAVOR)Craig M Zaidman, Crystal M Proud, Craig M McDonald, et al.
Annals of Neurology|October 3, 2009
Limb-girdle muscular dystrophy type 2D gene therapy restores alpha-sarcoglycan and associated proteinsJerry R Mendell, Louise R Rodino-Klapac, Xiomara Rosales-Quintero, et al.
BJR Open|November 13, 2023
Responsible AI practice and AI education are central to AI implementation: a rapid review for all medical imaging professionals in EuropeGemma Walsh, Nikolaos Stogiannos, Riaan van de Venter, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 11, 2017
Follistatin Gene Therapy for Sporadic Inclusion Body Myositis Improves Functional OutcomesJerry R Mendell, Zarife Sahenk, Samiah Al-Zaidy, et al.
British Journal of Sports Medicine|June 2, 2020
The Stanford Hall consensus statement for post-COVID-19 rehabilitationRobert M Barker-Davies, Oliver O'Sullivan, Kahawalage Pumi Prathima Senaratne, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 23, 2013
Vascular delivery of rAAVrh74.MCK.GALGT2 to the gastrocnemius muscle of the rhesus macaque stimulates the expression of dystrophin and laminin α2 surrogatesLouis G Chicoine, Louise R Rodino-Klapac, Guohong Shao, et al.
Pageof 38

Showing results (341-350 of 378) with videos related to

Sort By:
Pageof 38
Muscle & Nerve|August 14, 2023
Long-term safety and functional outcomes of delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy: A phase 1/2a nonrandomized trialJerry R Mendell, Zarife Sahenk, Kelly J Lehman, et al.
The New England Journal of Medicine|October 8, 2010
Dystrophin immunity in Duchenne's muscular dystrophyJerry R Mendell, Katherine Campbell, Louise Rodino-Klapac, et al.
Human Gene Therapy|March 7, 2019
Gene Delivery for Limb-Girdle Muscular Dystrophy Type 2D by Isolated Limb InfusionJerry R Mendell, Louis G Chicoine, Samiah A Al-Zaidy, et al.
Medical Physics|July 15, 2025
Comparison of three reconstruction algorithms for low-dose phase-contrast computed tomography of the breast with synchrotron radiationSandro Donato, Simone Caputo, Luca Brombal, et al.
Annals of Neurology|August 4, 2023
Delandistrogene Moxeparvovec Gene Therapy in Ambulatory Patients (Aged ≥4 to <8 Years) with Duchenne Muscular Dystrophy: 1-Year Interim Results from Study SRP-9001-103 (ENDEAVOR)Craig M Zaidman, Crystal M Proud, Craig M McDonald, et al.
Annals of Neurology|October 3, 2009
Limb-girdle muscular dystrophy type 2D gene therapy restores alpha-sarcoglycan and associated proteinsJerry R Mendell, Louise R Rodino-Klapac, Xiomara Rosales-Quintero, et al.
BJR Open|November 13, 2023
Responsible AI practice and AI education are central to AI implementation: a rapid review for all medical imaging professionals in EuropeGemma Walsh, Nikolaos Stogiannos, Riaan van de Venter, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 11, 2017
Follistatin Gene Therapy for Sporadic Inclusion Body Myositis Improves Functional OutcomesJerry R Mendell, Zarife Sahenk, Samiah Al-Zaidy, et al.
British Journal of Sports Medicine|June 2, 2020
The Stanford Hall consensus statement for post-COVID-19 rehabilitationRobert M Barker-Davies, Oliver O'Sullivan, Kahawalage Pumi Prathima Senaratne, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 23, 2013
Vascular delivery of rAAVrh74.MCK.GALGT2 to the gastrocnemius muscle of the rhesus macaque stimulates the expression of dystrophin and laminin α2 surrogatesLouis G Chicoine, Louise R Rodino-Klapac, Guohong Shao, et al.
Pageof 38